Eli Lilly racks up EUA for antibody cocktail — but the bigger challenge is still ahead
Eli Lilly has become the first drugmaker to have three Covid-19 treatments authorized for emergency use by the FDA, racking up an EUA for the use of its two-drug antibody cocktail to treat recently diagnosed patients with mild to moderate disease.
The regulatory clearance comes just two weeks after Lilly released a large batch of data from the BLAZE-1 trial showing that the combo of bamlanivimab and etesevimab reduced deaths and hospitalizations by 70% among 1,000 patients. But it arrives much later than the pharma giant had hoped: As early as October, following initial results around viral load, ER visits and hospitalization rate, Lilly said it had applied for an EUA.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 106,500+ biopharma pros reading Endpoints daily — and it's free.